279 related articles for article (PubMed ID: 19751468)
1. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.
Ginsberg HN; Maccallum PR
J Clin Hypertens (Greenwich); 2009 Sep; 11(9):520-7. PubMed ID: 19751468
[TBL] [Abstract][Full Text] [Related]
2. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus.
Ginsberg HN; MacCallum PR
J Cardiometab Syndr; 2009; 4(2):113-9. PubMed ID: 19614799
[TBL] [Abstract][Full Text] [Related]
3. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
4. Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors.
Ballantyne CM
Clin Cornerstone; 2007; 8 Suppl 6():S6-13. PubMed ID: 17948362
[TBL] [Abstract][Full Text] [Related]
5. Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.
Matikainen N; Taskinen MR
Curr Cardiol Rep; 2012 Dec; 14(6):721-31. PubMed ID: 22941588
[TBL] [Abstract][Full Text] [Related]
6. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
7. Management of diabetic dyslipidemia: need for reappraisal of the goals.
Khera A; McGuire DK
Am J Cardiovasc Drugs; 2005; 5(2):83-91. PubMed ID: 15725039
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.
Nakajima K
Curr Clin Pharmacol; 2010 May; 5(2):133-9. PubMed ID: 20156152
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes.
Rosenson RS; Reasner CA
Curr Opin Cardiol; 2004 Sep; 19(5):480-7. PubMed ID: 15316457
[TBL] [Abstract][Full Text] [Related]
10. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
[TBL] [Abstract][Full Text] [Related]
11. The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes.
Hoerger TJ; Ahmann AJ
J Manag Care Pharm; 2008 Feb; 14(1 Suppl C):S2-14; quiz 15-6. PubMed ID: 18240890
[TBL] [Abstract][Full Text] [Related]
12. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
[TBL] [Abstract][Full Text] [Related]
13. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
[TBL] [Abstract][Full Text] [Related]
14. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Davidson M
Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
[TBL] [Abstract][Full Text] [Related]
15. [Diabetic dyslipoproteinemia: beyond LDL].
Merkel M
Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
[TBL] [Abstract][Full Text] [Related]
16. Dyslipidemia and cardiovascular risk: the importance of early prevention.
Miller M
QJM; 2009 Sep; 102(9):657-67. PubMed ID: 19498039
[TBL] [Abstract][Full Text] [Related]
17. Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.
Pandian A; Arora A; Sperling LS; Khan BV
Vasc Health Risk Manag; 2008; 4(5):1001-9. PubMed ID: 19183748
[TBL] [Abstract][Full Text] [Related]
18. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
19. Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Kakafika AI; Liberopoulos EN; Karagiannis A; Athyros VG; Mikhailidis DP
Curr Vasc Pharmacol; 2006 Jul; 4(3):175-83. PubMed ID: 16842135
[TBL] [Abstract][Full Text] [Related]
20. Should all patients with metabolic syndrome be treated with statins?
Abate N; Chandalia M
Curr Diab Rep; 2006 Feb; 6(1):72-6. PubMed ID: 16522284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
